- Home
-
Technical Platform
-
Services
- TCR-T Lead Sequence Development Service
- Immune CAR Cell Preparation Technology Service
- Antibody Coupled Drug Discovery Service
- Antibody Affinity Maturation Service
- Antibody Humanization Services
- Bispecific Antibody Development Services
- Antibody Protein Sequencing Service
- Antibody Affinity Determination Service
Antibody Drugability Assessment
- Nucleic Acid Aptamer Synthesis Service
- Nucleic Acid Aptamer Modification Service
- Nucleic Acid Aptamer Library Construction Service
- Bispecific Aptamer Development Service
- Protein Nucleic Acid Aptamer Screening Service
- Metal Ion Nucleic Acid Aptamer Screening Service
- Small Molecule Nucleic Acid Aptamer Screening Service
- Cell Nucleic Acid Aptamer Screening Service
- Peptide Affinity Maturation Services
- Peptide-Drug Conjugate (PDC) Development Services
- Stapled Peptide Development Services
- Targeted Peptide Library Screening Service
- Targeted Peptide Library Construction Service
Active Peptide Discovery Technology Service
- mRNA Antibody Production Services
- mRNA Immunogen Production Service
- DNA Immune Antibody Preparation Service
Animal Immunization Technology Services
-
Technical Support
- Structural Basis for Selectivity and Antagonism in GPCR-Nanobodies
- Novel Peptide-Drug Conjugate (PDC) Shows Efficacy in Hepatocellular Carcinoma Models
- Nanobody Expression in Insect Cells
- Nanobody Mammalian Cell Expression
- Single-chain Antibody Library Construction Technology Introduction
- Prokaryotic Expression of Nanobodies
- Cell Line Immunogen of Nanobody
- Construction of Single Chain Antibody Library
- Nano-antibody/Single Domain Antibody Library Construction Service
- Customized Nano-antibody Immunogen3
- Cracking the Immune System’s “Source Code”: Why Is B-Cell Technology the Ultimate Path to Antibody Discovery?
- Five Golden Areas of Single B Cell Technology
- How much do you know about ADC drug development?
- Novel Cancer Therapeutic Strategy: Development of Bispecific Antibody-Drug Conjugates
- Nveiling the Molecular and Immunological Drivers of Antibody-Drug Conjugates (ADCs) in Cancer Treatment
- A PBD Dimer-Containing Antibody-Drug Conjugate (KK2845) Targeting TIM-3-Expressing AML
- A Novel Approach for Cancer Therapy - Modulating TCR Complex Recruitment to the T Cell Antigen Coupler (TAC) Enhances TAC-T Cell Function
- Development of Therapeutic Monoclonal Antibodies for Disease Treatment
- Common Problems and Solutions of Prokaryotic Expression of Recombinant Protein
- Neutralizing Monoclonal Antibody Development Service FAQ
Special topic on antibody modification
- Bacteriophages, yeast, mRNA display: Who is the champion of the display technology?
- Breakthrough: Ultra-High Sensitivity Detection of Legionella Using an Aptamer-Based Electrochemical Sensor
- Construction of yeast hybrid library: Gateway technology
- Eukaryotic System-Based Targeted Drug Discovery Platform: Yeast Display Technology
- Common Problems and Solutions for Yeast Two-hybrid Experiments
- Yeast Two-hybrid Technique Related Issues
- Common Problems and Solutions of Yeast Display Technology
- Overview of Yeast Two Hybrid System Principle and Application
- Introduction to Yeast Display Antibody Screening Technology
- Overview of Yeast Display Technology
Yeast Display Technology Special Topic
- Stop Sticking with Hybridoma! A Primer on the Three Generations of Antibody Discovery Technology
- Rationale and Significance of Bispecific Antibody Development
- Protein Not Expressing? You Might Have Chosen the Wrong Tag!
- What to Do After Protein Purification? These Four Validation Methods You Must Know!
- Yeast Two-Hybrid Technology Reveals a Novel Mechanism of Wheat Disease Resistance: How TaPIR1 "Hijacks" TaHRP1 to Suppress Chloroplast Function?
- Yeast Hybrid Library Construction: Smart Technology
- New Molecular Interaction Technology: How Much Do You Know About Yeast Hybridization Technology?
- Antibody Affinity Testing(SPR)
- Hybridoma Gene Sequencing Process
- Antibody Affinity Detection (BLI)
Antibody Detection Service Topic
- Application of phage display (Part 2)
- Application of phage display (Part 1)
- Phage Display
- Technical Article: Detailed Guide to Phage Screening
- Frontiers in Targeted Drug Development: Comparison and Application of Multiple Peptide Screening Methods
- Revolutionary Advances in Single-Domain Antibody Development and Applications
- New Method for Discovering Targeted Drugs: Screening of Peptide Libraries Based on Phage Display Technology
- How much do you know about IgG, Fab, scFv, and VHH?
- Novel Targeted Tumor Therapeutics: Efficacy of a Peptide-Drug Conjugate (PDC) in a Hepatocellular Carcinoma Model
- Non-Invasive In Vivo Monitoring of PROTAC-Mediated Protein Degradation Using an Environment-Sensitive Reporter
Special Topic on Phage Display Technology
- Discovery of targeted nucleic acid small molecules: Cell-SELEX technology
- A Promising Novel Cancer Therapeutic Strategy: Aptamer-Drug Conjugates (ApDCs)
- A Novel Therapeutic Approach for Multiple Myeloma: Development of a CD38 and CD47 Bispecific Bipartopic Antibody
- A Novel Therapeutic Approach - CAR-M
- Application And Prospects of CAR-T Technology in Tumor Immunotherapy
- CAR-T Discovery Service
CAR-T Molecule Discovery Topic
- The Promise of Small Nucleic Acid Therapeutics: From Bench to Clinic as Next-Generation Medicines
- Issues Related to Aptamer Library Screening
- Introduction to Nucleic Acid Aptamer Library Screening Technology
- Overview of Aptamer Synthesis Technology
- Screening and optimization of nucleic acid aptamers
- Screening and Application of Peptide Aptamers
- Main Research Directions Progress and Challenges of Nucleic Acid Aptamer Screening Technology
- Research Progress of Protein Nucleic Acid Aptamer Screening
- Research Progress of Aptamer Screening-of Small Molecule Targets
- Nucleic Acid Aptamer Libraries Screening: an Efficient Method for Discovering Specific Binding Molecules
Molecular Biology Service Topics
-
Product Center
- Contact Us
ADCs combine antibody specificity with cytotoxic payloads to treat hematologic and solid tumors. With diverse antigens, cleavable linkers, and novel payloads, they enhance efficacy. Toxicity management and novel formats remain key for expanding ADC applications.
CD7-ADC delivering BCL-XLi shows potent anti-T-ALL activity, spares platelets, and synergizes with venetoclax.
By comparing the principles, performance, and applicable scenarios of the three major display technologies—phage, yeast, and mRNA—we analyze the strengths and weaknesses of each technology in terms of library capacity, protein folding, and screening cycles. Leveraging its mature display technology platform, TekBio provides one-stop services for the development of various types of monoclonal antibodies and antibody optimization.
Antibodies derived from animal models are prone to ineffectiveness in humans and immune reactions, primarily due to their exogenous nature. Leveraging the immunological advantages of human B cells—such as natural antigen recognition and affinity maturation—Super SingleB? technology enables the efficient screening of high-quality fully human antibodies. TechBio has established a dedicated platform to provide one-stop antibody development services.
This article introduces applications of PhagePro Tech? phage display platform in peptide lead discovery, gene/cell therapy and diagnostic reagents. It describes screening strategies for penetrating/targeting peptides, phage-mediated bacterial gene delivery, CAR-T antibody screening and phage-based pathogen detection, and introduces Tek Biotechnology’s full-service antibody development platform.
PhagePro Tech? phage display technology enables difficult-target antibody development, optimized antibody humanization, vaccine mimotope screening and protein partner identification. Tech Biotech (Tianjin) offers one-stop VHH and neutralizing monoclonal antibody services for GPCR, tumor and disease targets, including library screening, affinity optimization and antibody developability evaluation.
TekBiotech is committed to providing scientists worldwide with high-quality single B cell antibody development services.
TekBiotech can provide scientists worldwide with high-quality monoclonal antibody development services covering various formats including scFv, VHH, and Fab.
TekBiotech is able to provide high-quality nucleic acid aptamer (including RNA aptamer and DNA aptamer) screening services to customers.
TekBiotech is committed to providing high-quality drug monoclonal antibody development services, including scFv, VHH, Fab, and other antibody formats, to scientists worldwide.
